bioCSL, formerly a part of CSL Biotherapies, manufactures and markets biological products for human use, in-licenses and markets vaccines and prescription pharmaceuticals to treat a range of human medical conditions as well as manufactures and markets in vitro diagnostic products.
Headquartered in Australia, bioCSL also has operations based in New Zealand and the USA. Vaccines manufactured by CSL are used in global markets. The international demand for CSL's influenza vaccine continues to grow as the benefits of protection from this life-threatening disease are more widely recognised around the world.
For information about the vaccines, anti-venoms, in-licensed pharmaceuticals and immunohaematology products (diagnostic reagents) that bioCSL distributes in Australia please visit the
bioCSL Australia website.
If you are interested in new partnerships regarding in-licensed pharmaceuticals, please visit the
bioCSL Australia website for more information.
CSL direct provides a convenient ordering portal for bioCSL products and Vaccines, visit the
CSL Direct website. If you would like more information about CSL direct, please contact CSL customer service on 1800 008 275.
bioCSL New Zealand
For information about prescription medicines and vaccines that bioCSL distributes in New Zealand visit the
bioCSL New Zealand website.
bioCSL United States*In December 2012, CSL announced that its plasma product operations in Australia will take on the name of its global plasma business, CSL Behring, and that the Company’s vaccine, pharmaceutical and diagnostics business will operate under the newly created name of bioCSL, effective 1 January 2013.
For information about influenza vaccines that bioCSL distributes in the USA visit the
bioCSL United States website.